Thioredoxin reductase inhibitors: updated patent review (2017-present)

References

• Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem. 1989;264(24):13963–13966.
   PubMed Web of Science ®Google Scholar
• Holmgren A, Johansson C, Berndt C, et al. Thiol redox control via thioredoxin and glutaredoxin systems. Biochem Soc Trans. 2005;33:1375–1377.
   PubMed Web of Science ®Google Scholar
• Bhatia M, McGrath KL, Di Trapani G, et al. The thioredoxin system in breast cancer cell invasion and migration. Redox Biol. 2016;8:8–78.
   Web of Science ®Google Scholar
• Karlenius TC, Tonissen KF. Thioredoxin and cancer: A role for thioredoxin in all 633 states of tumor oxygenation. Cancers (Basel). 2016;2:209–232.
   Google Scholar
• Nordberg J, Arnér ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med. 2001;31:1287–1312.
   PubMed Web of Science ®Google Scholar
• Holmgren A. Thioredoxin. Ann Rev Biochem. 1985;54:237–271.
   PubMed Web of Science ®Google Scholar
• Arnér E, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267:6102–6109.
   PubMedGoogle Scholar
• Powis G, Montfort WR. Properties and biological activities of thioredoxins. Ann Rev Pharmacol Toxicol. 2001;41:261–295.
   PubMed Web of Science ®Google Scholar
• Holmgren A, Sengupta R. The use of thiols by ribonucleotide reductase. Free Radic Biol Med. 2010;49:1617–1628.
   PubMed Web of Science ®Google Scholar
• Holmgren A, Johansson C, Berndt C, et al. Thiol redox control via thioredoxin and glutaredoxin systems. London: Portland Press Limited; 2005.
   Google Scholar
• Rodriguez R, Redman R. Balancing the generation and elimination of reactive oxygen species. Proc Natl Acad Sci USA. 2005;102:3175–3176.
   PubMed Web of Science ®Google Scholar
• Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006;10:175–176.
   PubMed Web of Science ®Google Scholar
• Benhar M, Shytaj IL, Stamler JS, et al. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clinical Invest. 2016;126:1630–1639.
   PubMed Web of Science ®Google Scholar
• Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Current Opinion Pharm. 2007;7:392–397.
   PubMed Web of Science ®Google Scholar
• Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther. 2005;4:13–20.
   Web of Science ®Google Scholar
• Bian M, Fan R, Zhao S, et al. Targeting the thioredoxin system as a strategy for cancer therapy. J Med Chem. 2019;62:7309–7321.
   PubMed Web of Science ®Google Scholar
• Li Q, Wall SB, Ren C, et al. Thioredoxin reductase inhibition attenuates neonatal hyperoxic lung injury and enhances nuclear factor E2–Related Factor 2 Activation. Am J Respir Cell Mol Biol. 2016;55:419–428.
   PubMed Web of Science ®Google Scholar
• Silva-Adaya D, Gonseblatt ME, Guevara J. Thioredoxin system regulation in the central nervous system: experimental models and clinical evidence. Oxid Med Cell Longev. 2014;590808.
   PubMed Web of Science ®Google Scholar
• Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004;3:205–214.
   PubMed Web of Science ®Google Scholar
• Prinz WA, Aslund F, Holmgren A, et al. The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm. J Biol Chem. 1997;272:15661–15667.
   PubMed Web of Science ®Google Scholar
• Lu J, Vlamis-Gardikas A, Kandasamy K, et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. Faseb J. 2013;27:1394–1403.
   PubMed Web of Science ®Google Scholar
• Gustafsson TN, Osman H, Werngren J, et al. Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis. Biochim Biophys Acta. 2016;1860:1265–1271.
   PubMed Web of Science ®Google Scholar
• Sannella AR, Casini A, Gabbiani C, et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett. 2008;582:844–847.
   PubMed Web of Science ®Google Scholar
• Angelucci F, Miele AE, Boumis G, et al. Macromolecular bases of antischistosomal therapy. Curr Top Med Chem. 2011;11:2012–2028.
   PubMed Web of Science ®Google Scholar
• Isakov E, Weisman-Shomer P, Benhar M. Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin. Biochim Biophys Acta. 2014;1840:3153–3161.
   PubMed Web of Science ®Google Scholar
• Shaw CF. Gold-Based Therapeutic Agents. Chem Rev. 1999;99:2589–2600.
   PubMed Web of Science ®Google Scholar
• Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008;16:112–125.
   PubMedGoogle Scholar
• Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol. 1997;36:560–572.
   PubMedGoogle Scholar
• Sun H, Yan SC, Cheng WS. Interaction of antimony tartrate with the tripeptide glutathione. Eur J Biochem. 2003;267:5450–5457.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02166242
   Google Scholar
• Zhang B, Zhang J, Peng S, et al. Thioredoxin reductase inhibitors: a patent review. Exp Opin Ther Patents. 2017;27:547–556.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li X, Han X, et al. Targeting the Thioredoxin System for Cancer Therapy. Trends Pharmacol Sci. 2017;38:794–808.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu Y, Li X, et al. Small Molecules to Target the selenoprotein thioredoxin reductase. Chem Asian J. 2018;13:3593–3600.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang B, Li X, et al. Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: an update. Med Res Rev. 2019;39:5–39.
   PubMed Web of Science ®Google Scholar
• Ghareeb H, Metanis N. The thioredoxin system: A promising target for cancer drug development. Chem Eur J. 2020;26:10175–10184.
   PubMed Web of Science ®Google Scholar
• Mohammadi F, Soltani A, Ghahremanloo A, et al. The thioredoxin system and cancer therapy: a review. Cancer Chemother Pharmacol. 2019;84:925–935.
   PubMed Web of Science ®Google Scholar
• Tavares TT, Azevedo GC, Garcia A, et al. Gold(I) complexes with aryl-thiosemicarbazones: molecular modeling, synthesis, cytotoxicity and TrxR inhibition. Polyhedron. 2017;132:95–104.
   Web of Science ®Google Scholar
• Reddy TS, Privér SH, Mirzadeh N. Bhargava SK: Anti-cancer gold(I) phosphine complexes: cyclic trimers and tetramers containing the P-Au-P moiety. J Inorg Biochem. 2017;175:1–8.
   PubMed Web of Science ®Google Scholar
• Reddy TS, Privér SH, Mirzadeh N. Bhargava SK: Synthesis of gold(I) phosphine complexes containing the 2-BrC6F4PPh2 ligand: Evaluation of anticancer activity in 2D and 3D spheroidal models of HeLa cancer cells. Eur J Med Chem. 2018;145:291–301.
   PubMed Web of Science ®Google Scholar
• Quero J, Cabello S, Fuertes T, et al. Cerrada E: proteasome versus thioredoxin reductase competition as possible biological targets in antitumor mixed thiolate-dithiocarbamate Gold(III) Complexes. Inorg Chem. 2018;57:10832–10845.
   PubMed Web of Science ®Google Scholar
• McCall R, Miles M, Lascuna P, et al. Dual targeting of the cancer antioxidant network with 1,4-naphthoquinone fused Gold(i) N-heterocyclic carbene complexes. Chem Sci. 2017;8:5918–5929.
   PubMed Web of Science ®Google Scholar
• Marzo T, Cirri D, Gabbiani C, et al. Auranofin, Et3PAuCl, and Et3PAuI are highly cytotoxic on colorectal cancer cells: a chemical and biological study. ACS Med Chem Lett. 2017;8:997–1001.
   PubMed Web of Science ®Google Scholar
• Fereidoonnezhad M, Ahmadi Mirsadeghi H, Abedanzadeh S, et al. Synthesis and biological evaluation of thiolate gold(i) complexes as thioredoxin reductase (TrxR) and glutathione reductase (GR) inhibitors. New J Chem. 2019;43:13173–13182.
   Web of Science ®Google Scholar
• Fan R, Bian M, Hu L, et al. A new rhodium(I) NHC complex inhibits TrxR: in vitro cytotoxicity and in vivo hepatocellular carcinoma suppression. Eur J Med Chem. 2019;183:111721.
   PubMed Web of Science ®Google Scholar
• Fan X-Y, Liu Y-J, Chen K, et al. Organic arsenicals target thioredoxin reductase followed by oxidative stress and mitochondrial dysfunction resulting in apoptosis. Eur J Med Chem. 2018;43:1090–1102.
   Google Scholar
• Fabbrini MG, Cirri D, Pratesi A, et al. I) Carbene complex with anticancer properties: synthesis, characterization, and biological studies. ChemMedChem. 2019;14:182–188.
   PubMed Web of Science ®Google Scholar
• Wang F-Y, Huang K-B, Feng H-W, et al. New Platinum(II) agent induces bimodal death of apoptosis and autophagy against A549 cancer cell. Free Radic Biol Med. 2018;129::418–429.
   PubMed Web of Science ®Google Scholar
• Du J, Wei Y, Zhao Y, et al. A Photoactive platinum(iv) anticancer complex inhibits thioredoxin–thioredoxin reductase system activity by induced oxidization of the protein. Inorg Chem. 2018;57:5575–5584.
   PubMed Web of Science ®Google Scholar
• Curran D, Dada O, Müller-Bunz H, et al. Synthesis and cytotoxicity studies of novel NHC*-Gold(I) complexes derived from lepidiline A. Molecules. 2018;23:2031.
   Web of Science ®Google Scholar
• Chen J, Zhang Y, Jie X, et al. Ruthenium(II) salicylate complexes inducing ROS-mediated apoptosis by targeting thioredoxin reductase. J Inorg Biochem. 2019;193:112–123.
   PubMed Web of Science ®Google Scholar
• Lam NYS, Truong D, Burmeister H, et al. From catalysis to cancer: toward structure–activity relationships for benzimidazol-2-ylidene-Derived N-Heterocyclic-carbene complexes as anticancer agents. Inorg Chem. 2018;57:14427–14434.
   PubMed Web of Science ®Google Scholar
• Abas E, Espallargas N, Burbello G, et al. Anticancer activity of alkynylgold(I) with P(NMe2)3 Phosphane in mouse colon tumors and human colon carcinoma caco-2 cell line. Inorg Chem. 2019;58:15536–15551.
   PubMed Web of Science ®Google Scholar
• Mármol I, Castellnou P, Alvarez R, et al. Alkynyl Gold(I) complexes derived from 3-hydroxyflavones as multi-targeted drugs against colon cancer. Eur J Med Chem. 2019;183:111661.
   PubMed Web of Science ®Google Scholar
• Florès O, Velic D, Mabrouk N, et al. Rapid synthesis and antiproliferative properties of polyazamacrocycle-based Bi- and Tetra-Gold(I) Phosphine Dithiocarbamate Complexes. ChemBioChem. 2019;20:2255–2261.
   PubMed Web of Science ®Google Scholar
• Landini I, Massai L, Cirri D, et al. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. J Inorg Biochem. 2020;208:111079.
   PubMed Web of Science ®Google Scholar
• Guarra F, Busto N, Guerri A, et al. Cytotoxic Ag(I) and Au(I) NHC-carbenes bind DNA and show TrxR inhibition. J Inorg Biochem. 2020;205:110998.
   PubMed Web of Science ®Google Scholar
• Dominelli B, Jakob CHG, Oberkofler J, et al. Mechanisms underlying the cytotoxic activity of syn/anti-isomers of dinuclear Au(I) NHC complexes. Eur J Med Chem. 2020;203:112576.
   PubMed Web of Science ®Google Scholar
• Bian M, Wang X, Sun Y, et al. Synthesis and biological evaluation of gold(III) Schiff base complexes for the treatment of hepatocellular carcinoma through attenuating TrxR activity. Eur J Med Chem. 2020;193:112234.
   PubMed Web of Science ®Google Scholar
• Tabrizi L, Abyar F. Conjugation of a gold(III) complex with vitamin B1 and chlorambucil derivatives: anticancer evaluation and mechanistic insights. Metallomics. 2020;12:721–731.
   PubMed Web of Science ®Google Scholar
• Truong D, Sullivan MP, Tong KKH, et al. Potent inhibition of thioredoxin reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl2 Complexes. Inorg Chem. 2020;59:3281–3289.
   PubMed Web of Science ®Google Scholar
• González-Barcia LM, Fernández-Fariña S, Rodríguez-Silva L, et al. Comparative study of the antitumoral activity of phosphine-thiosemicarbazone gold(I) complexes obtained by different methodologies. J Inorg Biochem. 2019;203:110931.
   PubMed Web of Science ®Google Scholar
• Abyar F, Tabrizi L. New cyclometalated gold (III) complex targeting thioredoxin reductase: exploring as cytotoxic agents and mechanistic insights. Biometals. 2020;33:107–122.
   PubMed Web of Science ®Google Scholar
• Sze JH, Raninga PV, Nakamura K, et al. Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma. Redox Biol. 2020;28:101310.
   Google Scholar
• Luo H, Cao B, Chan ASC, et al. Cyclometalated Gold(III)‐hydride complexes exhibit visible light‐induced thiol reactivity and act as potent photo‐activated anti‐cancer agents. Angew Chem Int Ed. 2020;59:11046–11052.
   PubMed Web of Science ®Google Scholar
• Li M, Shi X, Du L. 2017. A kind of gold triazole compound and its preparation method and application. CN105001244B.
   Google Scholar
• Arambula J, Arumugam K, Sessler JL, et al. 2020. Naphthoquinone containing gold carbene complexes and methods of uses thereof. US 20200216473.
   Google Scholar
• Gunkel N, Amtmann E, Morgen M, et al. 2020. Improved dithiocarbamate based compounds, therapies and diagnostics. WO 2020161337.
   Google Scholar
• Chen X, Luo H, Zou T. 2020. Photoresponsive cyclometalated gold(III) hydride, preparation method and applications thereof. CN 111004259.
   Google Scholar
• Fang J, Liu Y, Song ZL, et al. 2019. Organoarsenic compounds and uses thereof. CN 109369724.
   Google Scholar
• Holmgren A, Lu J. Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith. US. 2018;10:058,542.
   Google Scholar
• Zeng H, Yin H. 2020. Application of benzisoselenazole derivative and platinum drug in preparing drug for treating tumor and postoperative tumor recurrence. CN 110856718.
   Google Scholar
• Zeng H, Yin H. 2020. Tumor immunomodulator and application thereof. CN 110856717.
   Google Scholar
• Zeng H, Yin H. 2020. Application of benzo[d]isoselenazol derivatives in manufacturing medicament for treating tumor. CN 110801449.
   Google Scholar
• Zeng H, Yin H. 2020. Application of benzo[d]isoselenazol derivatives and antimetabolite in manufacture of medicament for treating tumor. CN 110801450.
   Google Scholar
• Gan -F-F, Kaminska KK, Yang H, et al. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity. Antiocid Redox Signal. 2013;19:1149–1165.
   PubMed Web of Science ®Google Scholar
• Ling Y, Yang S, Zhang Y, et al. 2020. Phenyl allylidene cyclohexanone derivatives and preparation method and use. WO 2020192348.
   Google Scholar
• Zhu P, Qian J, Xu Z, et al. Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling. J Nat Prod. 2020;83:3041–3049.
   PubMed Web of Science ®Google Scholar
• Miao LY, Changchun J, Li LX, et al. 2020. 6-Benzylidene-2-aryl athynyl cyclohexanone derivatives and its preparation method and medical use. CN 111018686.
   Google Scholar
• Qian J, Xu Z, Meng C, et al. Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy. Eur J Med Chem. 2020;204:112610.
   PubMed Web of Science ®Google Scholar
• Yang J, Weng Z, Pan Y, et al. 2020. Application of 2-(2,2,2-trifluoroethylene)-1,3-dione compound in preparing medicine for resisting lung cancer by promoting apoptosis. CN 111789830.
   Google Scholar
• Arner ESJ, Stafford WC, Coussens NP, et al. 2020. Tricyclic compounds and their use in the treatment of cancer. US 20200113889.
   Google Scholar
• Stafford WC, Coussens NP, Luci DK, et al. 2017. Pyridazinones and their use in the treatment of cancer. WO 2017027357.
   Google Scholar
• Landeta C, Meehan BM, McPartland L, et al. Inhibition of virulence-promoting disulfide bond formation enzyme DsbB is blocked by mutating residues in two distinct regions. J Biol Chem. 2017;292:6529–6541.
   PubMed Web of Science ®Google Scholar
• Stafford WC, Coussens NP, Luci DK, et al. 2017. Pyridines and their use in the treatment of cancer. WO 2017027359.
   Google Scholar
• Silvestri I, Lyu H, Fata F, et al. Fragment-Based Discovery of a Regulatory Site in Thioredoxin Glutathione Reductase Acting as “Doorstop” for NADPH Entry. ACS Chem Biol. 2018;13:2190–2202.
   PubMed Web of Science ®Google Scholar
• Pelcman B, Stafford W. 2020. Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer. US 20200024255.
   Google Scholar
• Pelcman B, Orwar O, Stafford W, et al. 2020. Sulfinylpyridines and their use in the treatment of cancer. US 20200024233.
   Google Scholar
• Zambaldo C, Vinogradova E, Qi X, et al. 2‑Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles. J Am Chem Soc. 2020;142:8972–8979.
   PubMed Web of Science ®Google Scholar
• Zhang B, Fang J. 2018. Uses of 2,4-dinitrobenzene sulfonamide compounds for the preparation of thioredoxin reductase inhibitors. CN 108451939.
   Google Scholar
• Gon Y-J, Xu W-Z, Zhang Y-P, et al. A novel weak acid activated probe for highly selective monitoring selenocysteine in living cells. Talanta. 2020;219:121287.
   PubMed Web of Science ®Google Scholar
• Gu Y, Zhao Z, Niu G, et al. Ratiometric detection of mitochondrial thiol with a two-photon active AIEgen. ACS Applied Bio Mater. 2019;2:3120–3127.
   Google Scholar
• Yang Y, Feng Y, Qiu F, et al. Dual-Site and Dual-Excitation fluorescent probe that can be tuned for discriminative detection of cysteine, homocysteine, and thiophenols. Anal Chem. 2018;90:14048–14055.
   PubMed Web of Science ®Google Scholar
• Fang J, Zhang B. 2018. 2,4-Dinitrophenyl ether compounds and applications thereof. CN 108276289.
   Google Scholar
• Zalubovskis R, Ivanova J, Domraceva I, et al. 2020. Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect. WO 2020170022.
   Google Scholar
• Altel TH, El-Awady RA, Vunnam S, et al. 2019. Novel heterocyclic systems and pharmaceutical compositions thereof. WO 2019186384.
   Google Scholar
• Koch O, Berling L. 2020. Mycobacterium tuberculosis-thioredoxin reductase inhibitor as an antitubercular agent. US 20200123130.
   Google Scholar
• Koch O, Jäger T, Heller K, et al. Identification of M. tuberculosis thioredoxin reductase inhibitors based on high-throughput docking using constraints. J Med Chem. 2013;56:4849–4859.
   PubMed Web of Science ®Google Scholar
• Chen W, Tuladhar A, Rolle S, et al. Rodriguez del Rey F, Zavala CE, Liu Y, Rein KS: brevetoxin-2, is a unique inhibitor of the C-terminal redox center of mammalian thioredoxin reductase-1. Toxicol Appl Pharmacol. 2017;329:58–66.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Liu D, Cheng W, et al. Versiquinazolines L–Q, new polycyclic alkaloids from the marine-derived fungus Aspergillus versicolor. RSC Adv. 2018;8(55):31427–31439.
   Web of Science ®Google Scholar
• He W, Cao P, Xia Y, et al. Zou P: potent inhibition of gastric cancer cells by a natural compound via inhibiting TrxR1 activity and activating ROS-mediated p38 MAPK pathway. Free Radic Res. 2019;53(1):104–114.
   PubMed Web of Science ®Google Scholar
• Liu R, Shi D, Zhang J, et al. Xanthatin promotes apoptosis via inhibiting thioredoxin reductase and eliciting oxidative stress. Mol Pharm. 2018;15(8):3285–3296.
   PubMedGoogle Scholar
• Wang C, Li S, Zhao J, et al. Design and SAR of withangulatin a analogues that act as covalent trxr inhibitors through the Michael addition reaction showing potential in cancer treatment. J Med Chem. 2020;63(19):11195–11214.
   PubMed Web of Science ®Google Scholar
• Tuladhar A. Rein KS: Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1). ACS Med Chem Lett. 2018;9:318–322.
   PubMed Web of Science ®Google Scholar
• Jayakumar S, Patwardhan RS, Pal D, et al. Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity. Free Radic Biol Med. 2017;113:530–538.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang B, Yan C, et al. A fast and specific fluorescent probe for thioredoxin reductase that works via disulphide bond cleavage. Nat Commun. 2019;10:2745.
   PubMed Web of Science ®Google Scholar
• Yao J, Duan D, Song Z-L, et al. Sanguinarine as a new chemical entity of thioredoxin reductase inhibitor to elicit oxidative stress and promote tumor cell apoptosis. Free Radic Biol Med. 2020;152:659–667.
   PubMed Web of Science ®Google Scholar
• Wanga Y, Zhang W, Donga J, et al. Design, synthesis and bioactivity evaluation of coumarin-chalcone hybrids as potential anticancer agents. Bioorg Chem. 2020;95:103530.
   PubMed Web of Science ®Google Scholar
• Ng H-L, Chew E-H, Chui W-K. Design, synthesis and biological evaluation of coupled bioactive scaffolds as potential anticancer agents for dual targeting of dihydrofolate reductase and thioredoxin reductase. J Med Chem. 2017;60:1734–1745.
   PubMed Web of Science ®Google Scholar
• Fan Q-Z, Zhou J, Zhu Y-B, et al. Zhang C: Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor. Bioorg Chem. 2020;105:104401.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Žalubovskis R, Grandāne A, et al. Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J Enzyme Inhib Med Chem. 2020;35:506–510.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Sharonova T, Sharoyko V, et al. Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity. J Enzyme Inhib Med Chem. 2020;35:665–671.
   PubMed Web of Science ®Google Scholar
• Han X, Zhang J, Shi D, et al. Fang J: targeting Thioredoxin Reductase by Ibrutinib Promotes Apoptosis of SMMC-7721 Cells. J Pharmacol Exp Ther. 2019;369:212–222.
   PubMed Web of Science ®Google Scholar
• Jovanović M, Zhukovsky D, Podolski-Renić A, et al. Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: identification of DVD-445 as a new lead compound for anticancer therapy. Eur J Med Chem. 2019;181:111580.
   PubMed Web of Science ®Google Scholar
• Jovanović M, Zhukovsky D, Podolski-Renić A, et al. Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: optimization of potency and evaluation of anticancer potential. Eur J Med Chem. 2020;191:112119.
   PubMed Web of Science ®Google Scholar
• Jovanović M, Dragoj M, Zhukovsky D, et al. Podolski-Renić A: novel TrxR1 inhibitors show potential for glioma treatment by suppressing the invasion and sensitizing glioma cells to chemotherapy. Front Mol Biosci. 2020;7:281.
   Web of Science ®Google Scholar
• Baell JB, Halloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from Screening Libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719–2740.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Somanathan R. Nitroaromatic compounds: environmental toxicity, carcinogenicity, mutagenicity, therapy and mechanism. J Appl Toxicol. 2014;34:810–824.
   PubMed Web of Science ®Google Scholar